甲基吡噁磷原药致突变性实验研究  

Empirical Study on the Mutagenicity of Azamethiphos Active Compound

作　　者：姜红[1] 高屹福[1] 杨卫超[1] 左派欣[1] 徐颖[1] 

机构地区：[1]河北省疾病预防控制中心卫生毒理所,河北石家庄050041

出　　处：《职业卫生与病伤》2006年第2期86-88,共3页Occupational Health and Damage

摘　　要：目的探讨甲基吡噁磷原药的致突变性,预测其遗传危害和潜在致癌作用的可能性。方法用昆明种小鼠经口灌胃染毒,骨髓微核实验的剂量分别为320、160、80、40mg/kg,睾丸细胞染色体畸变实验剂量为160、80、40mg/kg,分别取胸骨、睾丸组织,常规制片,镜下观察。鼠伤寒沙门氏菌回复突变(Ames)实验采用平板掺入法,剂量分别为0.50、1.25、2.50、5.00mg/皿。结果小鼠骨髓微核、睾丸细胞染色体畸变实验显示:甲基吡噁磷原药染毒组与阴性对照组相比,差异无统计学意义(P>0.05);Ames实验显示各菌株的各剂量组的回变菌落数均未超过自发回变菌落数的2倍。结论在本实验条件下,未发现甲基吡噁磷原药的致突变性。Objective To study the mutagenic effect of azamethiphos active compound, then to predict its genetic risk and the possibility of potential carcinogenic effect. Methods Kunming Jimpy mice were gavaged azamethiphos by mouth. The dose of bone marrow micronucleus test was 320 mg/kg, 160 mg/kg, 80 mg/kg and 40 mg/kg, respectively. The dose for chromosome abbreviated test of didyrnus cell was 160 mg/kg, 80 mg/kg and 40 mg/kg, respectively. Sterno- architecture and orchio - architecture were observed through conventional glass. Ames plate assay incorporation was used. The dose of Ames test was 0.5 mg/plate, 1.25 mg/plate, 2.50 mg/plate and 5.00 mg/plate, respectively. Results The dose for chromosome abbreviated testes of bone marrow micronucleus and didymus cell demonstrated that azamethiphos group did not show a significant difference form the negative control group （P〉0.05）. Ames test showed that azamethiphos group didn＇st cause double increases of revertants at all doses in every bacterial strains. Conclusions Azamethiphos might have no mutagenic effect in our experiment condition.

关 键 词：卫生杀虫剂 甲基吡嗯磷 致突变性 

分 类 号：R595.4[医药卫生—内科学]